INTRODUCTION
Obesity is a very significant health concern worldwide. Although obesity cannot be considered a disease by itself, it is strongly associated with the onset of insulin resistance, type II diabetes and cardiovascular diseases (1) . All of these reduce life expectancy and quality, produce early death and collapse obesityassociated care on health-care systems. Thus, investigating the mechanisms that support the development of obesity is important for the future discovery of treatments that prevent its occurrence and/or that of its associated disorders.
The expansion of adipose tissue in obesity is caused by an increase in adipocyte number (hyperplasia or adipogenesis) and/or adipocyte size (hypertrophy) (2) . Some studies in humans suggest that adipose mass in adulthood is determined by the tight regulation of the number of adipocytes (3) .
Adipogenesis is the complex process through which multipotent mesenchymal precursors commit to the adipocyte lineage and eventually mature into new adipocytes (2, 4) . Different models of in vitro adipocyte differentiation, including 3T3-L1 and cultured embryonic fibroblasts from mice have provided useful information to help unravel the cascade of events that take place during adipogenesis (5) . Under in vitro conditions, adipogenesis requires a period of growth arrest by contact inhibition that ends by treatment with adipogenic factors which promote preadipocytes to reenter the cell cycle and undergo one or two rounds of mitotic clonal expansion (MCE). Later, cells become permanently growth-arrested and undergo terminal adipocyte differentiation (6) (7) (8) . The morphological and genetic changes that occur during the process of adipogenic differentiation are regulated by a cascade of transcription factors. After adipogenic induction, cells immediately and transiently express C/EBPβ and C/EBPδ, implicated in the expression of C/EBPα, PPARγ and SREBP1c. C/EBPα and PPARγ help each other to maintain their elevated expression throughout the life of the adipocyte and activate the expression of most genes that confer and support the adipocyte phenotype, such as FABP4/aP2, GLUT4 and PLIN2/Adipophilin (9) (10) (11) . In vivo models of adipogenesis include the study of adipose tissue enlargement that follows high fat diet (HFD) (1) . cPLA 2  is one of the better known members of the PLA 2 superfamily of enzymes, whose common feature is to hydrolyze the fatty acid present in the sn-2 position of glycerophospholipids (12, 13) . cPLA 2  is widely expressed in mammalian cells, and is the only PLA 2 that shows preference for arachidonic acid (AA)-containing phospholipids as substrates (14) . During cellular stimulation its activity is regulated by phosphorylation and intracellular Ca 2+ concentrations (15) . A recent unexpected finding among the many functions attributed to cPLA 2  is that it is absolutely required for the biogenesis of lipid droplets in various types of cells (16) (17) (18) (19) . Adipocytes, also known as fat cells, are the cells where lipid droplets have a most prominent role because of their primary fat-storage function. In this regard, although mice lacking cPLA 2  and fed a HFD have been described to exhibit smaller epididymal fat pads and cPLA 2  is involved in adipogenesis adipocytes (20), virtually nothing is known about an involvement of cPLA 2  in adipose tissue function or even in the adipogenic process per se.
Using multipotent adipose-derived stem cells (ASCs), mouse embryonic fibroblast (MEFs) and cell lines, we identify in this work cPLA 2  as an early key factor for adipocyte differentiation in vitro.
Furthermore, using cPLA 2  KO animals we also reveal a role for this enzyme during high fat diet (HFD)-induced obesity.
EXPERIMENTAL PROCEDURES
Reagents-Antibodies against β-Actin (A5441) were obtained from Sigma-Aldrich (St. Louis, MO, USA). Antibodies against PPARγ (07-466) and FABP4/aP2 (AB3515) were purchased from Merck Millipore Corp. (Billerica, MA, USA). Antibodies against C/EBPα (2295), C/EBPβ (3087), cPLA 2  (2832) and P(Ser505)-cPLA 2  (2831) were obtained from Cell Signaling Technology (Barcelona, Spain).
Antibodes against Cdk2 (643901) and Cyclin A (644001) were from BioLegend (San Diego, CA, USA).
Antibodies against the nuclear matrix protein p84 (ab487) were from Abcam (Cambridge, UK) and against p115 (612260) were from BD Biosciences (Franklin Lakes, NJ, USA).
Cell culture and differentiation-3T3-L1 preadipocytes (ATCC CL-173) were maintained in
Dulbecco's modified Eagle's medium (DMEM) (Thermo Fisher Scientific Inc., Waltham, MA, USA) containing 10% neonatal calf serum (Thermo Fisher Scientific Inc.) plus 2 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin and 25 mM HEPES in a humidified incubator with 5% CO 2 . Two days after confluence (differentiation day 0) medium was replaced with DMEM containing 5 μg/ml insulin, 0.5 mM IBMX, 0.25 μM dexamethasone and 10% fetal bovine serum (FBS) (Thermo Fisher Scientific Inc.) (adipogenic differentiation medium 1, ADM1). Two days later, medium was replaced with DMEM containing 5 μg/ml insulin and 10% FBS (ADM2). After three days cells were maintained in medium containing 10 % FBS (adipocyte culture medium).
NIH/3T3 (ATCC CRL-1658) were maintained DMEM containing 10% FBS plus 2 mM Lglutamine, 100 U/ml penicillin, 100 μg/ml streptomycin and 25 mM HEPES, and primary MEFs from 14.5-day mouse embryos were maintained DMEM F-12 containing 10% FBS plus 100 U/ml penicillin and 100 μg/ml streptomycin.
Cells were differentiated according to the protocol described for 3T3-L1 cells, but ADM2 and adipocyte culture medium were supplemented with 10 μM of pioglitazone. Also, the concentration of insulin used for MEFs was 10 μg/ml.
Adipocytes and their precursor cells (ASCs) from murine Swiss epididymal white adipose tissue were isolated by collagenase digestion, as previously described (21). Cells from the stromal-vascular fraction were cultured on tissue culture plates and were maintained in DMEM F-12 containing 10% FBS cPLA 2  is involved in adipogenesis plus 100 U/ml penicillin and 100 μg/ml streptomycin in a humidified incubator with 5% CO 2 . Cells attaching to the plates constitute ASCs, which were trypsinized and cryopreserved or reseeded. ASCs were differentiated two days after confluence by adding medium containing 10 μg/ml insulin, 0.5 mM IBMX, 1 μM dexamethasone and 200 μM indomethacin. The medium was changed every 3 days and fully differentiated cells were analyzed after 9 days of culture.
Animals-cPLA 2  -/-(Pla2g4a −/− ) mice and wild type littermates were backcrossed onto the C57BL/6 mice (Japan SLC) for more than 12 generations (22). Animals were kept at 23 °C free of pathogens in a 12-h light-dark cycle without restrictions for water or food consumption. At 8 weeks of age, females were changed to a HFD with 32% of crude fat (HFD 32; CLEA Japan) for 16 weeks (23).
All procedures were performed in accordance with approvals by the Institutional Animal Care and Use
Committees of Tokyo Metropolitan Institute of Medical Science, Showa University, Japan.
MTT assay-Cell viability was assessed by using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium-bromide (MTT) assay (Sigma-Aldrich). This reagent is reduced by living cells to form an insoluble blue formazan product that can be quantified by absorbance at 570 nm. Cells were treated with 0.5 mg/ml MTT and incubated for 4 h in a CO 2 incubator. Then, cell supernantants were aspirated, cells were treated with isopropanol 100% for 10 min and formazan production was quantified using VersaMax Tunable Microplate Reader (Molecular Devices, Sunnyvale, USA).
FACS analysis-Cells were trypsinized and collected by centrifugation, washed with PBS, and then fixed in 70% (v/v) cold methanol. Fixed cells were washed with PBS and stained with 50 μg/ml propidium iodide (PI) (Sigma-Aldrich) in the presence of 200 μg/ml RNase A (Sigma-Aldrich) in PBS in the dark for 1 hour. Labeled cells were analyzed using a flow cytometry system Gallios™ (Beckman Coultec, Barcelona, Spain), and data were analyzed using the KaluzaTM software.
Immunoblot-Cells were lysed with 20 mM Tris-HCl (pH 7.4), containing 150 mM NaCl, 0.5% Triton X-100, 1mM Na 3 VO 4 , 1 mM NaF, 1 mM PMSF (Sigma-Aldrich) and a protease inhibitor cocktail (Sigma-Aldrich) at 4 °C. Homogenates were then clarified by centrifugation at 16,000 x g for 10 min and supernatants used for further analysis.
Extraction of cytoplasmic and nuclear proteins was performed by resuspending the cells in 10 mM Tris-HCl (pH 7.5) containing 10 mM NaCl, 3 mM MgCl 2 , 100M EGTA, 100 μM Na 3 VO 4 , 1 mM PMSF, a protease inhibitor cocktail (Sigma-Aldrich), 0,5 mM Dithiothreitol (Sigma-Aldrich) and 0,05% NP-40 (Merck Millipore Corp.). The cytoplasmic fraction was then clarified by centrifugation at 8000 x g for 2 min. The pellet containing the nuclei was lysed with 20 mM HEPES (pH 7.9), containing 420 mM NaCl, 1,5 mM MgCl 2 , 100 M EDTA, 100 μM Na 3 VO 4 , 25% glycerol, 1 mM PMSF and a protease inhibitor cocktail. The nuclear fraction was then clarified by centrifugation at 16000 x g for 10 min and supernatants used for further analysis. Adipocytes 3T3-L1 were transfected with 3 μg of plasmid by electroporation using a Gene Pulse Xcell (Bio-Rad laboratories, Hercules, CA, USA).
AA release assay-Evaluation of AA release was performed as previously described (27). In brief, the cells were labeled with 0.5 Ci/ml of [5, 6, 8, 9, 11, 12, 14, 15 -3H]AA (Sigma-Aldrich) for 20 h. Cells were then washed, treated with the differentiation cocktail and supernatants were removed for radioactivity quantification. Cell monolayers were overlaid with ice-cold PBS containing 0.05% Triton X-100 and scraped. Radioactivity was quantified by liquid scintillation counting in supernatants and homogenates, and AA release was referred to total radioactivity for each condition.
Lipid analysis-Lipids form mice gonadal adipose tissue were extracted using the method described by Folch (28). Lipid classes were separated by thin layer chromatography and their composition in fatty acids were analysed by GC/MS as previously described (18, 29) .
Histology and adipocyte quantification-Samples of gonadal adipose tissue were fixed in paraformaldehyde, embedded in paraffin, cut, and stained with hematoxylin and eosin (23). From micrographs pictures, the area of randomly selected adipocytes was measured using the ImageJ image analysis software. After calculating the frequency distribution for the areas, adipocyte number in WAT was calculated as previously described (30).
Statistics-All values are given as means ± SEM. Differences between two groups were assessed by using the unpaired Student's t-test. A p value < 0.05 was considered statistically significant.
RESULTS
cPLA 2  decreases its expression levels during adipogenesisWe started this work by looking for possible differences in the expression levels of PLA 2 family members between stromal-vascular fraction (SVF) cells, which include adipocyte precursors, and adipocytes isolated from white adipose tissue of mice. We noted significant increases in mRNA levels of some PLA 2 s, namely Groups IIE, VIA, VIB, VID, VIE and XVI ( Figure 1A ), but a very specific change was the disappearance of the mRNA for the Multipotent cells such as the NIH/3T3 cell line and the preadipocytic cell line 3T3-L1, were also used in these studies, using siRNA technology to decrease cPLA 2  (Figures 3D-E, and 4). The same behavior as described above was observed in the absence of cPLA 2 . Collectively, these data demonstrate that adipocyte precursors need cPLA 2  to completely differentiate into adipocytes. Reduction of cPLA 2  expression significantly affected the release of AA, confirming the importance of the enzyme in the process ( Figure 5B ). The time-course of AA release paralleled the phosphorylation of the enzyme in Ser 505 , which is a hallmark of activation ( Figure 5C ). We found that FBS caused the same level of phosphorylation as the complete ADM1 ( Figure 5D ). By analyzing the localization of cPLA 2  during the differentiation of 3T3-L1 cells, we found that the enzyme exhibits a cytosolic diffuse localization in preadipocytes, while it localizes mainly in the Golgi in fully differentiated adipocytes (colocalization with the Golgi specific protein p115) (Figures 5E and F). Analogous localization of cPLA 2  is involved in adipogenesis cPLA 2  in the absence of high intracellular Ca 2+ levels has been associated with inactivation of the enzyme (31). Taken together, these data suggest that cPLA 2  acts early during adipocyte differentiation.
cPLA 2  affects several early processes after adipogenic inductionNext, we investigated which of the early events of adipocyte differentiation process were affected by abrogation of cPLA 2  expression. Mitotic clonal expansion is a well documented event that occurs very early during the differentiation process and is required for adipocyte differentiation (8) . We found that 3T3-L1 treated with siRNA against cPLA 2  experienced diminished proliferation levels than control cells for the first two days after adipogenic induction ( Figure 6A ). Cell cycle analyses by flow cytometry demonstrated that, while the majority of control cells were at the G 2 /M phase of the cell cycle after 24 h of adipogenic induction, cells with reduced levels of cPLA 2  underwent a delay that retained many of them in the first phases of the cell cycle ( Figure 6B and C). In agreement with these findings, we found that key factors for cell cycle progression such as Cyclin A or Cdk2 had a delayed expression in cells expressing reduced levels of cPLA 2  ( Figure 6D ).
Expression of very early transcription factors like C/EBP was also delayed in cPLA 2 -deficient cells ( Figure 6E ). As a consequence of it, the expression of transcription factors that are controlled by C/EBP, like C/EBP and SREBP-1c had a reduced expression that could already be noticed at day 2 after adipogenic induction ( Figure 4F ). These data indicate that cPLA 2  is important for early adipogenic events.
Exogenous AA during the cell-contact inhibition state enhances adipogenesisAll the cell systems used in this work show reduced expression levels of cPLA 2  at the time of adipogenic induction.
Thus we reasoned that at least part of the proadipogenic function of cPLA 2  could be exerted in the preadipocyte when its expression levels are higher. To obtain experimental support for this suggestion, we treated preadipocytes 3T3-L1 with exogenous AA 2 days prior to induction of adipogenesis, i.e. when proliferation of cells is inhibited by cell contact (confluence phase). As shown in animals ( Figures 9B-C) . Also, white adipose tissue (WAT) but not brown adipose tissue (BAT) weight was affected, suggesting a role for cPLA 2  in the first tissue but not in the second one ( Figure 9D ). and a significant increase in the mRNA for the preadipocytic marker Pref-1 ( Figure 9J ).
Together, the data indicate that cPLA 2  participates in adipogenesis (hyperplasia), and lipid accumulation (hypertrophy) that occur in the adipose tissue during feeding a HFD.
DISCUSSION
The present study shows that cPLA 2  is required for adipogenesis of multipotent cells such as
MEFs and the cell line NIH/3T3, and the committed preadipocytic cell line 3T3-L1. These data provide support for a key role for cPLA 2  in in vitro differentiation. Furthermore, animals deficient in cPLA 2  that are subjected to a HFD show a reduced capacity to increase body weight and fat mass, confirming the important role for the enzyme during the enlargement of the adipose tissue in these circumstances.
cPLA 2  is a unique enzyme within the PLA 2 superfamily in many respects. For instance, cPLA 2  is the only PLA 2 that shows marked preference for AA chains within glycerophospholipids; it translocates to intracellular membranes in response to an intracellular Ca 2+ rise, and is phosphorylated by MAPKs during activation (12, 15, 32) . The present study adds another interesting unique feature for this enzyme, namely cPLA 2  plays a fundamental role at the very beginning of the differentiation affecting adipocyte generation. In most cells, cPLA 2  expression levels are generally stable, its activity being tightly cPLA 2  is involved in adipogenesis regulated by events triggered after receptor stimulation (12, 15, 26, 33, 34) . The finding that during adipogenesis, cPLA 2  levels fall sharply is a striking behavior for this enzyme under physiologicallyrelevant conditions. Cell treatment with glucocorticoids has previously been related with decreases in cPLA 2  expression levels by affecting de novo mRNA synthesis (35). During adipocytic differentiation in vitro, the glucocorticoid dexamethasone, which is present in the differentiation cocktail, may account for the reduction in enzyme levels. Interestingly, we have also detected an important reduction in the levels of cPLA 2  mRNA and protein between SVF cells and adipocytes from mouse adipose tissue, provably reflecting that the natural adipocyte differentiation process also proceeds with a reduction of the enzyme.
Whether this effect is related with glucocorticoid levels generated during adipogenesis in vivo remains to be elucidated. PKA and phosphorylation of the transcription factor CREB (36, 37). In this sense, it has been described that AA can substitute for IBMX, the molecule present in the adipogenic cocktail that increases cAMP levels during the induction of adipocyte differentiation (38) . However, if AA and IBMX are added together to preadipocytes, there is a reduction of adipogenesis that can be restored with PKA inhibitors (38) . These effects suggest that under these conditions the levels of cAMP are very high and produce detrimental effects on adipogenesis. However, in a natural adipogenic process where IBMX is not present and cAMP levels are not high, cPLA 2  could contribute to the generation of cAMP and the propagation of downstream effects. Consistent with this is our finding that pretreatment of preadipocytes with AA during two days without IBMX, promotes adipogenesis.
Our in vivo studies show that cPLA 2  plays a role in regulating the expression of C/EBPβ and SREBP-1c during HFD. SREBP-1c is a target for C/EBPβ during adipogenesis, and then their expression levels are connected (39) . The function of SREBP-1c in adipogenesis is to regulate the expression of lipid metabolism genes and also the production of endogenous PPAR ligands (11, 40) . This suggests that, although the expression of PPAR is not affected by cPLA 2  in animals on a HFD, its activation level could be determined by the endogenous ligands produced by SREBP-1c, impacting in this way the differentiation process. Thus, by regulating the levels of C/EBP and SREBP-1c, cPLA 2  determines the levels of both adipogenesis and adipocyte hypertrophy in vivo.
cPLA 2  is involved in adipogenesis
Not only ASCs exhibit high levels of cPLA 2  in the adipose tissue, but macrophages also are very rich sources of this enzyme (41) . These are cells with a very high capacity to release AA when activated by many different stimuli ( 42, 43) . In the adipose tissue, obesity promotes the infiltration of macrophages, which may account for up to 60% of all cells in the tissue (44), likely increasing the capacity of the tissue to generate AA from phospholipid stores. There are several effectors produced under these circumstances that may act to increase AA release by the macrophages. For example, palmitic acid produced by aberrant lipolysis on stressed adipocytes could activate TLR4 on the surface of macrophages (42) . Also, enhanced production of TNF during obesity could impact on macrophages to release AA (45) . Collectively, the possibility exist that in obesity, activated macrophages that are part of the stromal-vascular fraction of cells, and are very proximal to ASCs, release substantial amounts of AA that in a paracrine manner would impact in ASCs increasing adipogenesis of these cells. In support of this view, it has been shown that there is a very strong correlation between adipocyte size and the content on macrophages of the adipose tissue (44) .
Collectively our data show that cPLA 2  is a positive regulator of adipogenesis. cPLA 2  regulates early adipogenic processes related with the expression of transcription factors and cell cycle progression during the mitotic clonal expansion associated to adipogenesis. Also, in obesity, cPLA 2  is involved in adipose tissue expansion, and neutral lipids deposition. Future research should evaluate how pharmacological inhibition of the enzyme could affect obesity and its related comorbidities. Belmonte, N., Phillips, B. W., Massiera, F., Villageois, P., Wdziekonski, B., Saint-Marc, P., Nichols, J., Aubert, J., Saeki, K., You, A., Narumiya, S., Ailhaud, G., and Dani, C. (2001)
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